A
AVIDITY BIOSCIENCES INC
NASDAQ: RNA (Avidity Biosciences, Inc.)
Last update: 9 hours ago27.05
-1.36 (-4.79%)
| Previous Close | 28.41 |
| Open | 28.79 |
| Volume | 1,626,864 |
| Avg. Volume (3M) | 1,172,631 |
| Market Cap | 3,227,308,288 |
| Price / Sales | 372.40 |
| Price / Book | 3.04 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -4,200.94% |
| Diluted EPS (TTM) | -2.88 |
| Quarterly Revenue Growth (YOY) | -17.10% |
| Total Debt/Equity (MRQ) | 0.51% |
| Current Ratio (MRQ) | 17.76 |
| Operating Cash Flow (TTM) | -184.50 M |
| Levered Free Cash Flow (TTM) | -135.19 M |
| Return on Assets (TTM) | -18.33% |
| Return on Equity (TTM) | -27.76% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Avidity Biosciences, Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.83% |
| % Held by Institutions | 106.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (TD Cowen, 188.36%) | Buy |
| Median | 67.00 (147.69%) | |
| Low | 60.00 (Needham, 121.81%) | Buy |
| Average | 68.40 (152.87%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 44.99 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 10 Jan 2025 | 72.00 (166.17%) | Buy | 29.46 |
| 20 Dec 2024 | 72.00 (166.17%) | Buy | 31.82 | |
| RBC Capital | 26 Nov 2024 | 67.00 (147.69%) | Buy | 43.80 |
| Chardan Capital | 13 Nov 2024 | 65.00 (140.30%) | Buy | 52.50 |
| 30 Oct 2024 | 65.00 (140.30%) | Buy | 43.22 | |
| Needham | 13 Nov 2024 | 60.00 (121.81%) | Buy | 52.50 |
| 31 Oct 2024 | 60.00 (121.81%) | Buy | 42.26 | |
| TD Cowen | 21 Oct 2024 | 78.00 (188.35%) | Buy | 46.71 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |